Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic adjuvant chemotherapy for soft tissue sarcomas

M M Zalupski1, L H Baker

  • 1Division of Hematology and Oncology, Wayne State University, Detroit, Michigan, USA.

Hematology/Oncology Clinics of North America
|August 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study.

Leukemia·2010
Same author

Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2003
Same author

Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
Same author

Combined-modality therapy in pancreatic cancer: current status and future directions.

Cancer journal (Sudbury, Mass.)·2001
Same author

Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma.

Cancer·2001
Same author

Phase II study of liposomal doxorubicin in patients with advanced colorectal cancer.

American journal of clinical oncology·2001
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Adjuvant chemotherapy for soft tissue sarcoma is still under investigation. Ongoing clinical trials, like the National Cancer Institute

Area of Science:

  • Oncology
  • Surgical Oncology
  • Medical Oncology

Background:

  • Adjuvant chemotherapy for soft tissue sarcoma is currently investigational.
  • Multidisciplinary treatment programs are a priority for high-grade sarcomas.
  • The role of adjuvant chemotherapy in soft tissue sarcoma treatment is debated.

Purpose of the Study:

  • To assess the efficacy of adjuvant chemotherapy in soft tissue sarcoma.
  • To contribute to the ongoing debate regarding adjuvant chemotherapy in sarcoma treatment.
  • To provide a foundation for future research through a better understanding of sarcoma biology.

Main Methods:

  • A randomized clinical trial is being conducted by the National Cancer Institute.
  • The trial compares postoperative adjuvant doxorubicin and ifosfamide with observation.

Related Experiment Videos

  • The study focuses on patients with high-grade sarcoma.

    • Main Results:

    • Results are pending completion of the randomized clinical trial.
    • Outcomes will inform the debate on adjuvant chemotherapy's role.

    Conclusions:

    • Further investigation and clinical trials are necessary.
    • Understanding the underlying biology of soft tissue sarcoma is crucial for future research.
    • The ongoing National Cancer Institute trial is expected to provide significant data.